Welcome to the Settlement Website for the Reata Securities Litigation.
The Court-appointed Lead Plaintiff, UMC Benefit Board, Inc., US Equity Fund-P Series, a series of the Wespath Funds Trust, US Equity Index Fund-P Series, a series of the Wespath Funds Trust, Wespath Institutional Investments LLC, US Equity Fund-I Series, a series of Wespath Funds Trust, and US Equity Index Fund-I Series, a series of the Wespath Funds Trust (“Wespath” or “Lead Plaintiff”), on behalf of itself and the Settlement Class (defined below), has reached a settlement with defendant Reata Pharmaceuticals, Inc. (“Reata” or the “Company”), the Individual Defendants (as defined in the Stipulation of Settlement (“Stipulation”)), and the Underwriter Defendants (as defined in the Stipulation) (collectively the “Defendants”) for $45,000,000 in cash that will resolve all claims in the Action (the “Settlement”).
If you are a member of the Settlement Class, your rights will be affected, and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
All persons or entities who purchased or otherwise acquired the publicly traded common stock of Reata between November 14, 2016 and December 8, 2021, inclusive (the “Settlement Class Period”), including all persons or entities who purchased or otherwise acquired Reata common stock pursuant and/or traceable to Reata’s 2019 Offering and/or 2020 Offering (the “Offerings Subclass”).
If you are a member of the Settlement Class, to be potentially eligible to receive a payment under the Settlement, you must have submitted a Claim Form no later than April 24, 2024. On March 29, 2024, the Court approved the Settlement and Plan of Allocation. Payments to Authorized Claimants will be made after the completion of all claims processing.
Please read the Notice to fully understand your rights and options. The Frequently Asked Questions page of this website has more information on your rights as a member of the Settlement Class.